在住院心脏骤停后预测30天的生存期:使用机器学习和SHAP分析进行全国性队列研究
Vibha Gupta1,2,3, Aidin Rawshani4, Peter Lundgren4,3,5
1Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden gupta85vibha19085@gmail.com.
BMJ open
|April 27, 2025
概括
一个新的机器学习模型准确地预测了医院内心脏骤停 (IHCA) 后的30天生存期. 像上腺素和初始节奏这样的关键预测因素可以改善IHCA患者的临床决策.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 医疗保健中的机器学习
背景情况:
- 住院心脏骤停 (IHCA) 的存活率很低.
- 预测IHCA后的30天生存率是具有挑战性的,目前的工具缺乏解释性.
- 对IHCA结果需要准确和可解释的预测模型.
研究的目的:
- 开发一种机器学习 (ML) 模型,用于预测IHCA后的30天生存期.
- 通过使用Shapley添加式解释 (SHAP) 识别生存的关键围捕预测因素.
- 确保该模型平衡了预测准确性和临床解释性.
主要方法:
- 全国范围的基于登记的观察性研究,使用瑞典心肺复苏登记数据 (2010-2020年).
- 对25905例IHCA病例进行了分析,试图进行复苏.
- 开发和验证一个CatBoost ML模型,使用五倍交叉验证和SHAP进行解释性.
主要成果:
- CatBoost 模型实现了高预测性能 (AUROC 0.9136).
- 确定的主要预测因素包括上腺素的管理,年龄,初始节奏和目击逮捕.
- 该模型表现出强大的校准和高灵敏度,低假负率.
结论:
- 开发的CatBoost模型是预测30天IHCA生存的有效和可解释的工具.
- 确定了关键预测因素,可以为IHCA管理中的临床决策提供信息.
- 该模型具有强大的临床实用性,并可通过开放访问API进行外部验证.
相关概念视频
01:21Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
01:24Kaplan-Meier Approach
52
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
52
01:20Actuarial Approach
39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39